Catalyst

Slingshot members are tracking this event:

Data read out from PRONTO Phase 2b evaluating NEOD001 in patients with a primary diagnosis of AL Amyloidosis and cardiac dysfunction - Discontinued

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
PRTA

100%

Additional Information

Management Comment Our maximum screening period by protocol is 28 days with an average screening time to date of approximately 19 days. Accordingly, we expect all patients in screening to complete that process sometime in March. This is a 12-month study and accounting for time for database lock and data analysis, we expect to announce results in the second quarter of 2018. The primary endpoint of the PRONTO study is cardiac test response is defined by a change in NT-proBMP.
https://seekingalpha...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 23, 2018
Occurred Source:
Related Keywords Neod001, Pronto, Al Amyloidosis, Nt-probmp, Discontinued